17 results
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
15 Nov 18
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018
4:02pm
at 2018 Foundation for Prader-Willi Research Annual Conference (FPWR)
Data presented indicate that DCCR targets the underlying neural mechanisms
424B5
SLNO
Soleno Therapeutics Inc
6 May 24
Prospectus supplement for primary offering
4:58pm
and perpetuation of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex … , accumulation of excess body fat and the establishment and perpetuation of the obese state.
DCCR’s unique mode of action with targets in the brain
S-3ASR
SLNO
Soleno Therapeutics Inc
2 Jan 24
Automatic shelf registration
4:06pm
of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex
424B5
68e3 65mf7i1bi
2 May 24
Prospectus supplement for primary offering
4:04pm
424B5
7cdth
16 Jul 21
Prospectus supplement for primary offering
4:07pm
424B5
7c59yfg
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
nihyo
27 Sep 23
Prospectus supplement for primary offering
5:26pm
424B5
xqx95rt1p
28 Mar 22
Prospectus supplement for primary offering
4:53pm
424B5
2xf32x7up7
30 Mar 22
Prospectus supplement for primary offering
5:21pm
S-1/A
djdwb2lmdgabdbl7f
1 Jul 14
IPO registration (amended)
12:00am
- Prev
- 1
- Next